Related Experiment Video
Updated: May 30, 2026
06:12
Intracerebral Transplantation and In Vivo Bioluminescence Tracking of Human Neural Progenitor Cells in the Mouse Brain
Published on: January 27, 2022
Intrabody applications in neurological disorders: progress and future prospects.
1Wadsworth Center, New York State Department of Health, and Department of Biomedical Sciences, University at Albany, Albany, NY 12201, USA.
Summary
Intrabodies, engineered from single-chain antibodies, show promise for treating neurodegenerative diseases by targeting misfolded proteins. This technology offers new therapeutic avenues for conditions like Huntington's, Parkinson's, and Alzheimer's diseases.
Area of Science:
- Biotechnology
- Neuroscience
- Immunology
Background:
- Single-chain variable fragments (scFv) and single-domain antibodies (sdAbs) mimic full-length antibody binding.
- These can be selected in vitro via phage or yeast display and expressed intracellularly as intrabodies.
- Intrabodies can modulate protein folding, interactions, modifications, and localization within cells.
Purpose of the Study:
- To review the application of intrabody technology to neurodegenerative diseases.
- To highlight the potential of intrabodies as therapeutics and drug discovery tools for neurological disorders.
Main Methods:
- In vitro selection of antibody fragments from naive human repertoires.
- Intracellular expression of selected antibody fragments (intrabodies) in mammalian cells.
- Review of studies targeting neurodegenerative disease-associated proteins.
Main Results:
- Intrabody technology has been successfully applied to Huntington's disease models.
- Early-stage development of anti-synuclein and anti-beta-amyloid intrabodies is underway.
- Research in Parkinson's, Alzheimer's, and prion diseases supports intrabody development.
Conclusions:
- Intrabodies represent a promising therapeutic strategy for neurodegenerative diseases.
- Targeting specific misfolded proteins or common downstream effectors offers novel treatment options.
- Intrabodies can serve as valuable tools for drug discovery in neurodegeneration.
Related Concept Videos
01:29Drug Delivery: Parenteral Route
The parenteral route is a critical method of drug administration. It delivers compounds directly into the systemic circulation and bypasses the gastrointestinal tract. This approach is particularly advantageous for drugs that exhibit poor absorption or instability when administered orally.
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
There are three primary parenteral routes: intravenous (IV), intramuscular (IM), and subcutaneous (SC). The IV route introduces the drug directly into the bloodstream, ensuring immediate action. The IM route...
01:14Brain Imaging
Brain imaging technologies provide critical insights into both the structure and function of the human brain, enabling medical professionals and researchers to diagnose, study, and treat neurological disorders or psychiatric disorders more effectively.
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).
These technologies include computerized axial tomography (CAT or CT scans), positron-emission tomography (PET scans), magnetic resonance imaging (MRI), functional magnetic resonance imaging (fMRI), and Transcranial Magnetic Stimulation (TMS).